Review of NICE Technology Appraisal Guidance No.187; Infliximab and adalimumab for the treatment of Crohn's disease

 Proposal to update the existing guidance

 TA187 was added to the static list in March 2011. In March 2015 the Institute considered the available evidence and decided that the guidance should remain on the static list as no new robust new evidence was available that would be likely to lead to a change in the existing recommendations.

 The Institute is now proposing to undertake a partial update of the clinical guideline on Crohn's disease management (CG152). During surveillance a considerable amount of evidence was identified which assessed the efficacy of anti-TNF therapy for maintenance of remission of Crohn’s disease after surgery.

Currently TA187 does not provide any recommendations for anti-TNF therapy for maintenance of remission of Crohn’s disease after surgery. The update to CG152 provides an appropriate context for these recommendations to be made, especially as the recommendations can then be placed into wider context within clinical practice.

 Consequently we propose that TA187 should be updated in the forthcoming partial update of the clinical guideline CG152. Upon the publication of the new clinical guideline, TA187 will be superseded and the guidance withdrawn

 In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance.

 Please see appendix A for a full list of the organisations we have contacted. 

 


This page was last updated: 28 July 2017